The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization  by Nordon, Clementine et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 7 5 – 8 11098-3015$36.00 – s
Published by Elsevie
http://dx.doi.org/10
E-mail: clementi
* Address correspojournal homepage: www.elsevier .com/ locate / jva lComparative Effectiveness Research/Health Technology Assessment (HTA)The “Efﬁcacy-Effectiveness Gap”: Historical Background and
Current Conceptualization
Clementine Nordon, MD PhD1,*, Helene Karcher, PhD2, Rolf H.H. Groenwold, PhD3,
Mikkel Zöllner Ankarfeldt, PhD4, Franz Pichler, PhD5, Helene Chevrou-Severac, PhD6,
Michel Rossignol, MD, PhD7, Adeline Abbe, MSc8, Lucien Abenhaim, MD, PhD2,
on behalf of the GetReal consortium
1LASER Research, Paris, France; 2LASER Analytica, London, UK; 3Julius Centre for Health Sciences and Primary Care, University
Medical Centre Utrecht, Utrecht, The Netherlands; 4Novo Nordisk A/S, Soborg, Denmark; 5Eli Lilly and Company, Melrose Park,
Australia; 6Takeda Pharmaceuticals International, Glattpark-Opﬁkon, Switzerland; 7Department of Epidemiology, Biostatistics and
Occupational Health, McGill University, Montreal, Quebec, Canada; 8Sanoﬁ R&D, Chilly Mazarin, FranceA B S T R A C TBackground: The concept of the “efﬁcacy-effectiveness gap” (EEG) has
started to challenge conﬁdence in decisions made for drugs when
based on randomized controlled trials alone. Launched by the Inno-
vative Medicines Initiative, the GetReal project aims to improve
understanding of how to reconcile evidence to support efﬁcacy and
effectiveness and at proposing operational solutions. Objectives: The
objectives of the present narrative review were 1) to understand the
historical background in which the concept of the EEG has emerged
and 2) to describe the conceptualization of EEG. Methods: A focused
literature review was conducted across the gray literature and articles
published in English reporting insights on the EEG concept. The
identiﬁcation of different “paradigms” was performed by simple
inductive analysis of the documents’ content. Results: The literature
on the EEG falls into three major paradigms, in which EEG is relatedee front matter Copyright & 2016, International S
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ndence to: Clementine Nordon, LASER Research, 1to 1) real-life characteristics of the health care system; 2) the method
used to measure the drug’s effect; and 3) a complex interaction
between the drug’s biological effect and contextual factors. Conclu-
sions: The third paradigm provides an opportunity to look beyond
any dichotomy between “standardized” versus “real-life” character-
istics of the health care system and study designs. Namely, future
research will determine whether the identiﬁcation of these contextual
factors can help to best design randomized controlled trials that
provide better estimates of drugs’ effectiveness.
Keywords: efﬁcacy-effectiveness gap, pragmatic clinical trials,
outcomes research, pharmaceuticals.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Regulatory approval of a new drug requires evidence of a positive
efﬁcacy-safety ratio: the extent to which the drug does more good
than harm [1] is usually measured using randomized controlled
trials (RCTs). Prelaunch drug development relies heavily on RCTs.
When new drugs are launched in the market, little is known
about their impact under routine prescribing practice and uti-
lization of drugs, conventionally known as effectiveness [2]. The
concept of the “efﬁcacy-effectiveness gap” (EEG) describes possi-
ble discrepancies and complementary scientiﬁc evidence on
efﬁcacy and effectiveness. The awareness raised around this
concept [3–5] results from how it may impact clinical and policy
decisions on drugs. Research initiatives that aim to improve
understanding of how evidence of efﬁcacy and effectiveness
can be reconciled and introduced at an earlier stage of drug
development have been launched worldwide [6,7].In the context of the GetReal project [7], the objectives of this
narrative review on the EEG were 1) to understand the historical
background in which the concept of EEG has emerged and 2) to
describe the conceptualization of EEG.Methods
A narrative-focused literature review of documents published in
English to synthesize knowledge on EEG and address the objec-
tives set out by the authors was carried out.
Identiﬁcation of Documents
First, a broad search of the gray literature was performed
across Internet Web sites from governmental authorities [8,9]
and nongovernmental initiatives for EEG [6,9–12], as well asociety for Pharmacoeconomics and Outcomes Research (ISPOR).
0, place de Catalogne, 75014 Paris, France.
Table 1 – Search algorithm on the “efﬁcacy-effectiveness gap”.
Efﬁcacy
1 Efﬁcacy efﬁcacy [Title/Abstract]
2 Clinical trials “Clinical Trial, Phase II” [Publication Type] OR “Clinical Trial, Phase III” [Publication Type] OR “Clinical Trial, Phase
IV” [Publication Type] OR “Controlled Clinical Trial” [Publication Type] OR “Multicenter Study” [Publication Type]
OR “Randomized Controlled Trial” [Publication Type] OR “Clinical Trials, Phase II as Topic” [Mesh] OR “Clinical
Trials, Phase III as Topic “[Mesh] OR “Clinical Trials, Phase IV as Topic” [Mesh] OR “Controlled Clinical Trials as
Topic” [Mesh] OR “Multicenter Studies as Topic” [Mesh] OR clinical trial*[Title/Abstract] OR clinical trial*[Text
Word] OR “randomized” [Title/Abstract] OR “randomized” [Title/Abstract] OR “randomized” [Text Word] OR
“randomised” [Text Word] OR “randomization” [Title/Abstract] OR “randomization” [Title/Abstract] OR
“randomization” [Text Word] OR “randomization” [Text Word] OR “random allocation” [Title/Abstract] OR
“double blind” [Title/Abstract] OR “double blinded” [Title/Abstract] OR “double masked” [Title/Abstract] OR
“single blind” [Title/Abstract] OR “single blinded” [Title/Abstract] OR “single masked” [Title/Abstract]
3 Explanatory
trials
Explanatory [Title/Abstract] AND (trials [Title/Abstract] OR trial [Title/Abstract] OR studies [Title/Abstract] OR
study [Title/Abstract])
4 1 AND (2 OR 3)
Effectiveness
5 Effectiveness Effectiveness [Title/Abstract] OR “translational research” [Title/Abstract]
6 Real life (“Real Life” [Title/Abstract]) AND (study [Title/Abstract] OR studies [Title/Abstract])) OR (“real word” AND study)
[Title/Abstract] OR (“real word” AND data*) [Title/Abstract] OR (observational [Title/Abstract] AND (study [Title/
Abstract] OR studies [Title/Abstract])) OR (“Real Life” [Title/Abstract] AND conditions [Title/Abstract]) OR
naturalistic [Title/Abstract] OR “patient-oriented research” [Title/Abstract]
7 CER “comparative effectiveness” [Title/Abstract] OR CER [Title/Abstract]
8 Pragmatic
studies
(Pragmatic [Title/Abstract] OR Practical [Title/Abstract]) AND (trials [Title/Abstract] OR trial [Title/Abstract] OR
studies [Title/Abstract] OR study [Title/Abstract])
9 5 AND (6 OR 7 OR 8)
Concept
10 Gap Gap*[Title/Abstract] OR issue*[Title/Abstract] OR complexit*[Title/Abstract] OR barrier*[Title/Abstract] OR
facilitator*[Title/Abstract] OR problem*[Title/Abstract] OR bias [Title/Abstract]
11 4 AND 9 AND 10
CER, cost-effectiveness research.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 7 5 – 8 176Google and Google Scholar (for books and theses). This approach
identiﬁed key authors and the main keywords to be used sub-
sequently in a focused literature search (second step). This search
was performed applying an algorithm (see Table 1) to the Embase,
PubMed, and Cochrane Collaboration Web sites. Finally, the
search was completed using a “snowball method” across the
reference lists from the articles identiﬁed. The search ended
when saturation was reached and no additional information
relating to the identiﬁed paradigms could be extracted.
Selection and Appraisal of Documents
Documents were selected when 1) providing key elements about
the historical background in which the EEG concept emerged and
2) when reporting insights (deﬁnitions and solutions) on the EEG
concept. Quality appraisal of the document was performed
ensuring “relevance” and “clarity” of the research questions, both
regarding the qualitative research [13] and unprompted judg-
ment, that is, our expertise [14].
Analysis and Data Synthesis
To identify different “paradigms,” all the selected documents
were used to extract and synthetize how the phenomenon of
interest (EEG) was understood or discussed (the authors’ perspec-
tive). A simple inductive analysis of the documents’ content was
performed because no paradigm classiﬁcation had been deﬁned
before our study. The identiﬁcation of different items took place
as the data were being collected and analyzed. One researcher (C.
N.) read the documents and annotated the main items in the
margins. Subsequently, other researchers were involved (L.A. and
M.R.), proceeding to a more analytical listing of items and the
identiﬁcation of paradigms.Results
Search Results
The search algorithm allowed the identiﬁcation of 672 academic
manuscripts after removing duplicates. These were screened on
title, and for a further 100 articles, the abstracts or the full
manuscript was read.Historical Background
The growing number of available medical technologies since the
1950s and the increasing amount of related information have
generated a need for rigorous assessment of the potential beneﬁt
[15], information synthesis, and knowledge dissemination [16] of
medical interventions.Standardization of Trials and Information Synthesis
The standardization of clinical trials started in the 1950s with the
implementation of founding principles for RCTs [17], but the
importance of basing the assessment of therapies through
clinical trials—rather than relying on prescribers’ “opinions” [18]
—reached the wider medical community nearly 20 years later.
During this period, the concept of “attitude” [19] in a trial
(explanatory vs. pragmatic) was introduced: the “explanatory
attitude” related to the objective of acquiring information about
the efﬁcacy of drugs, whereas the “pragmatic attitude” related to
the objective of gaining information about their effectiveness.
These two attitudes were described as leading to two ways of
interpreting results: understanding versus making decisions. The
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than 20 years.
In turn, methods for synthetizing the information from
several clinical trials (meta-analyses) were standardized between
1980 and the early 1990s [20]. The Cochrane Collaboration [21]
was created to facilitate the development of systematic reviews
and meta-analyses of RCTs.
Knowledge dissemination
The creation of the American Consensus Development Program
[22] in 1977 was an early attempt to improve the dissemination
of biomedical research into clinical practice. Similarly, the
paradigm of evidence-based medicine (EBM) emerged to pro-
mote good clinical practice [23] and was presented as “a
practice integrating individual clinical expertise with the best
available external clinical evidence from systematic research”
[24]. (Fig. 1).
The EEG
Notwithstanding the standardization of clinical trials, methods to
synthetize evidence, and platforms for knowledge dissemination,
a chasm between research and clinical practice [25] has been
noted and called the “knowledge gap” [22] or the “efﬁcacy-
effectiveness gap” [26]. Lehman et al. [26] explained: “Effective-
ness refers to the impact of treatment under usual treatment
conditions, in which patient factors […], provider factors […], and
service system factors […] that can affect treatment outcomes,
are not controlled.”
Over the years, several ways of understanding the EEG have
been suggested. Through our literature review, we have identiﬁed
that the EEG concept falls into three major paradigms (see
Table 2) relating to the role of 1) health care settings, 2) methods
used to assess drugs’ effect, and 3) the interaction between the
drug and contextual factors.
First Paradigm: The Issue of Behavior Toward Drugs’
Prescription and Use
In a ﬁrst paradigm, the EEG may be explained by characteristics
of health care settings, including the “behavior” of caregivers and
patients’ adherence to treatment. In this paradigm, the optimal
effect of the drug is thought to be distorted by real-life factors;
namely, the EEG is understood as an issue of behavior.
First, the physicians’ behavior has been thought to jeopardize
the effectiveness of drugs and the dissemination of knowledge.* Zubrod, C.G. Multiclinic trials in cancer chemotherapy. Can Med Assoc J 97, 1
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Fig. 1 – Historical background of the eOne example can be found in a book published by the American
Institute of Medicine, in which the authors stated that “patterns
of medical practice often diverge from recommendations based
on controlled clinical evaluations” [27, p. 176] and explained that
one reason for this relates to physicians’ behavior, deﬁned as a
combination of skepticism about innovation, lack of medical
training, characteristics of the practice setting, and so forth.
However, RCTs were thought to be the strongest method of
assessing the efﬁcacy of drugs. Similarly, it has been suggested
that cognitive biases in interpreting new results (e.g., the ten-
dency to embrace evidence supporting preconceived ideas) may
compromise the generation and dissemination of evidence on
efﬁcacy into practice [28]. It is noteworthy that because clinical
research and medical care involve human beings—physicians
and patients—subjectivity cannot be set aside [29].
Second, the patients’ adherence (i.e., the extent to which a
patient’s behavior corresponds to agreed recommendations from
a health care provider [30]) has been suggested as a key factor to
explain EEG, especially in chronic disorders [31–33]. The under-
lying rationale is that in clinical trials, attempts are made to
maximize adherence, which would not be the case in daily
practice. Numerous adherence-enhancement strategies have
been developed (cognitive-educational interventions, self-
reporting devices, or even telephone coaching [34]). Their impact
on medication adherence, however, was found to be modest and
not sustained over time [35]. In turn, the impact of enhancing
medication adherence on effectiveness is yet to be established.
Also, the relationship between the effect of a drug and drug
adherence is complex and may apply in both directions: bad
adherence by patients may lower the impact of treatments, and
the poor efﬁcacy (or tolerance) of a drug as perceived by the
patient may lower the patient’s adherence, in particular for
medications that are expected to have a direct and identiﬁable
effect on symptoms. In recognition of this intricate relationship,
the investigators of a large pragmatic trial on antipsychotic drugs
[36] have used the “discontinuation of treatment for any cause”
as the primary outcome, explaining that “this measure integrates
patients’ and clinicians’ judgments of efﬁcacy, safety, and toler-
ability into a global measure of effectiveness […].”
Finally, the disparity in resource and access to care between
settings has been considered as being responsible for the EEG
[37,38]. For example, in elderly people with depression [39],
the EEG has been described as the result of a combination of
health care–related factors and intricate barriers, categorized
into “patient barriers” (e.g., high costs of care, misdiagnosis of01-3 (1967) 
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Table 2 – Summary of the three paradigms identiﬁed.
Paradigm Description Themes encompassed
1. The EEG is related to real-
life characteristics of the
health care system
The ideal effect of the drug is distorted by real-life
characteristics of the health care system, related
to the physician, the patient, and access to
health care resources
 In routine practice, the physicians’ “behavior”
regarding medical guidelines and dissemination of
knowledge is not optimal
 In routine practice, the patients’ adherence is not
optimal
 In routine practice, there are access barriers to
health care resources
2. The EEG is related to an
issue of the method used
to measure the drug’s
effect
Efﬁcacy and effectiveness studies use different
study designs and design parameters, hence the
EEG
 Concept of evidence-based medicine and hierarchy of
evidence: the efﬁcacy is the real effect of the drug;
the RCTs are the criterion standard for measuring
the drug’s effect
 Concept of pragmatism: RCTs’ lack of
generalizability; any direct dissemination of
evidence coming from clinical trial into clinical
practice is inadequate
3. The EEG is related to an
issue of complex
interaction
The drug’s effect is the result of complex (and
multiple) interactions between the biological
effect of the drug and “real-life” contextual
factors, hence the EEG
 Some contextual factors are (signiﬁcantly)
interacting with the drug’s biological effect
(“drivers of effectiveness”)
 An imbalance in the distribution of these factors
between efﬁcacy and effectiveness studies may
cause an EEG
EEG, efﬁcacy-effectiveness gap; RCT, randomized controlled trial.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 7 5 – 8 178depression in elderly people, and older people rarely seeking
care), “provider barriers” (e.g., competing care of comorbidities),
and “policy barriers” (e.g., geographic distance from care pro-
vider). It is believed that facilitating access to care could improve
medical outcomes, as exempliﬁed in a study on the “easy access
to ambulatory service” program by patients with bipolar disorder
[40].
Second Paradigm: The Issue of Method Used and Measure
A second paradigm holds that the EEG may be explained by the
different study designs and methods being used to assess the
impact of drugs (efﬁcacy vs. effectiveness studies). In short, the
EEG is understood here as an issue of method/measure in which
the difference in effect size would stand in a difference relating to
the study design.
There is indeed an association between the choice in study
design parameters and the drug’s effect size, as evidenced by
Naudet et al. [41], who have investigated the impact of several
design parameters of RCTs versus observational studies on the
effect size of antidepressants. One of the reported results referred
to the use of double blinding (vs. none), the comparison against
placebo (vs. active comparator), or the use of intention-to-treat
analyses (vs. per-protocol) as being associated with a lower effect
size, regardless of patients and disease characteristics.
One ﬁnding of our literature review, however, is that within
this paradigm, two concepts are opposed [42]: the concept of
“hierarchy of evidence” supporting the superiority of RCT (due to
a supposedly better internal validity) over nonrandomized stud-
ies, and the concept of “pragmatism” arguing that RCTs would
lack generalizability (external validity) as compared with more
pragmatic studies.
The Concept of Hierarchy of Evidence
The development of EBM and the concept of hierarchy of
evidence might have introduced ambiguity regarding the role of
RCTs within the frame of health technology assessment, with the
underlying assumption that efﬁcacy would be the real effect of
the drug whereas effectiveness would be a distorted one, derivedfrom “biased” real-life observational studies [43,44]. In a publica-
tion on EBM [24], its authors simultaneously stated that RCT “has
become the gold standard for judging whether a treatment does
more good than harm” and that EBM “is the conscientious,
explicit, and judicious use of current best evidence in making
decisions about the care of individual patients,” which might have
blurred the essential difference between assessing drugs’ efﬁcacy
and choosing between drugs in clinical practice [19]. Further-
more, the concept of hierarchy of evidence [45] has consolidated
RCTs and meta-analyses of RCTs as the leaders among type of
studies aiming at assessing drugs’ impact. This concept holds
that the quality of study designs is set in stone, irrespective of the
study objective, that is, whether it is intending to measure the
biologic effect of the drug or not, or informing prescribers or
policymakers on the best options to choose from in routine
practice. Although a more balanced use of this hierarchy of
evidence has been recently suggested [46,47], the concept of
hierarchy of evidence may have contributed to the idea that
“real-life” studies are not as legitimate as RCTs to provide
evidence on the effect of drugs.The Concept of “Pragmatism”
Conversely, it has been argued that RCTs lack generalizability.
The “cautious generalization” of clinical trials was emphasized a
long time ago [17], as well as the necessity to interpret results of
clinical trials within the context of routine practice, using, for
instance, the physicians’ expertise [22]. The limited general-
izability of RCTs, however, has been explained in more detail
only recently. Many aspects of the traditional RCT design do not
represent routine clinical practice: the selection of the population
[48–50], its homogeneity [5], interventions not reﬂecting routine
practice [51], and outcomes often not relevant enough for clini-
cians and patients [25]. The concept of pragmatism holds that
this lack of generalizability has led to an EEG and that any direct
dissemination of evidence arising from clinical trials into
clinical practice might be inadequate [52,53]. In line with this
concept, the generation of real-life evidence on the impact of
drugs is becoming increasingly recommended, namely, for
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seen as complementary [55–57].
Third Paradigm: The Issue of Increased Variability and
Interaction
More recently, a third paradigm has been developed in which any
quantitative difference in drugs effect estimates, as measured in
an experimental setting or in routine practice, may be under-
stood as the result of interaction of multiple real-life character-
istics on the purely biological effect of the drug. Eichler et al. [5]
have explained that “to a large extent, the EEG may be considered
a result of increasing variability of drug response owing to a
combination of genetic, other biological and behavioral factors.”
The factors of potentially increasing variability in real life were
categorized into 1) intrinsic biological characteristics of patients
(genetics, physiology, comorbidities, etc.); 2) extrinsic environ-
mental factors (diet, air pollution, health care system character-
istics, etc.); and 3) behavioral factors (off-label prescriptions,
patient adherence, etc.).
This paradigm encompasses the ﬁrst two paradigms described
earlier and also brings the EEG concept into a more operational
level: if the EEG is related to the increasing variability (or the
modiﬁcation) of real-life factors, which statistically speaking
corresponds to effect modiﬁcation and/or interaction, then this
gap may not only be explained but can also be anticipated and
predicted.
To illustrate this paradigm, we report one study by Schnee-
weiss et al. [58], who have applied the patients’ eligibility criteria
commonly used in RCTs on statins to an observational study
population, by sequentially excluding prevalent drug users,
patients with contraindications, or patients with low adherence
and so forth. They have examined the extent to which the 1-year
mortality rate ratio estimates were changed and evidenced that
using more restrictive eligibility criteria modiﬁed the mortality
rate ratio estimates to the levels found in RCTs. These results
suggest the existence of some interaction effect of patients’
characteristics on the association between statins and mortality.
On the same line, Ankarfeldt et al. [59] explored the impact of a
high protein diet on weight change when RCTs and observational
studies showed conﬂicting results. The authors suggested that
being overweight and obese—which characterize the patients
included in RCTs but not to the same extent, the patients
included in observational studies—can act as an effect modiﬁer
on the association between a high protein diet and weight
change. Another illustration is provided by Chassang et al. [60]
who explored the impact of blinding (vs. open label) on the effect
size of antidepressants. In line with Naudet et al. [41], the authors
found that in double-blind RCTs, the treatment response tends to
be smaller than in open-label studies because there is no
“patients’ beliefs effect” (expectancies over active treatment,
leading to a patients’ change in behavior) in double-blind RCTs.
Although not new, the study results demonstrate—both through
mathematical formalization and through empirical data analyses
—that a difference in treatment effect size can happen only in the
presence of interaction. This article provides a clear and formal
demonstration of the role of interaction in the EEG.Discussion
The present article is the result of extensive literature review on
the EEG focusing on the current understanding of this concept.
Main Results
The present narrative study is thought to be the ﬁrst to review
the literature on the EEG, so as to reﬂect the whole spectrum ofits conceptualization and to elicit the scientiﬁc paradigms that
have inﬂuenced physicians and decision makers for decades.Three Main Paradigms Render the EEG
A ﬁrst paradigm holds that imperfections of the health care
system in real life may explain why effectiveness outcomes are
disappointing compared with efﬁcacy outcomes. Thus, it is
believed that all aspects of care in real life should be brought
up to the standards of the experimental setting, with several
levels of intervention: medical guidelines, knowledge dissemina-
tion, adherence-enhancement strategies, and so forth. These
interventions are certainly commendable efforts to be made.
The actual impact of such interventions, however, would be
difﬁcult to assess. Of note, this paradigm is not considering the
possibility of the effectiveness being superior to the efﬁcacy. One
can imagine that the patient-physician relationship is a lever to
patients’ adherence, hence a better outcome in real life. Similarly,
it is possible (and desirable) that in routine practice, physicians
choose between therapeutic options so as to maximize the
chance of success in one particular patient. A second paradigm
advocates that the methodology used to measure a drug’s effect
(efﬁcacy vs. effectiveness) has an impact on the drug’s outcome,
hence the EEG. Although this is probably often the case, one
output of this review is that most of the debate has been focused
on the pros and cons of each study design option. This debate is
somewhat sterile because efﬁcacy and effectiveness studies
actually address different but complementary questions. In their
pursuit of recognizing the complementary importance of explan-
atory and pragmatic designs, some authors have introduced the
idea of “the explanatory-pragmatic continuum” [61]. Finally, a
third paradigm has been identiﬁed, championing that a drug’s
therapeutic impact is the result of complex interactions between
the drug’s biologic effects and contextual factors (patient-related,
provider-related, and health care–related). These interactions are
at play whatever the study setting or design, but may differ in
magnitude as a result of a drug being assessed in standardized
(RCT) or in more ﬂexible (real-life) conditions, hence the discrep-
ancies in results. This third paradigm encompasses the ﬁrst two
and provides the opportunity to look beyond any dichotomy
between standardized versus real-life behavior of physicians/
patients, or between study designs/methods. Moreover, it may
provide promising implications for future research.Practical Implications for Researchers
The third paradigm provides a general research framework that
allows the identiﬁcation of those contextual factors interacting
with the drug that have a particular impact on its effectiveness
(“drivers of effectiveness”).
All contextual factors may not equally impact a potential EEG.
For instance, in the study by Schneeweiss et al. [58], several
“levels of restriction”were applied to a cohort study population to
replicate ﬁnding of RCTs, but did not share a similar impact on
estimates for effects on statins: the restriction on “incident users”
(by excluding prevalent users) had a greater impact than did the
restriction on “adherent patients” (by excluding nonadherent
patients). Through this example, we may hypothesize that the
“incident/prevalent user” characteristic “drives” the effectiveness
of statins, whereas “adherence” does not. This hypothesis, which
of course would need to be further addressed, has practical
implications in the design of an RCT to establish the effectiveness
of statins among all potential users, including new users and
possible switchers. A practical implication in designing an RCT
on statins would be to include both incident and prevalent users,
so as to be able to take this factor into account and minimize the
risk of an EEG.
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might depend on the drug and the disease under investigation.
For instance, the choice between a double-blind or open-label
design was found to inﬂuence antidepressants’ effect estimates
[41,60] because treatment expectancies on the treatment’s effect
are high in depression but this might not be the case for other
drugs or diseases.
The implications for future research are numerous. The
identiﬁcation of the most impactful contextual factors may help
to better design RCTs and if the latter are to be designed in a
more “pragmatic” way [10], the emphasis in pragmatism should
be put on these impactful contextual factors. Also, the contextual
factors that are most likely to cause an EEG need to be identiﬁed
“case by case,” that is, for each disease area.
Study Limitations
First, the present review was not exhaustive but was not aimed to
be so. The literature published on the EEG is extensive, and a
selection was made using predeﬁned criteria (publication in
English, peer-reviewed articles, subjective appraisal of articles’
quality). Also, the “snowball method” is thought to identify the
most cited articles, usually published in journals in the higher
impact factor scale range [62]. A selection bias preventing us from
identifying all the existing paradigms on the EEG, however,
cannot be excluded.
Second, our study focused on the gap in effectiveness out-
comes and did not explore a gap in safety or beneﬁt-risk ratio
outcomes. Purposely made, this choice meets the objectives of
the GetReal project, allowing us to better frame our research to
that end. A gap in safety outcomes, however, may exist exactly in
the same way as it does for effectiveness outcomes. The articles
reviewed in the present study often discussed the two kinds of
outcomes indifferently. For instance, Nallamothu et al. [50] have
provided examples for a gap in knowledge in the risk of hyper-
kalemia in patients taking aldactone, which was underestimated
in RCTs. Hernan et al. [63] have investigated the discrepancies of
results between cohort studies and RCTs regarding the risk of
coronary heart disease in women subject to hormone replace-
ment therapy. The authors have evidenced that this discrepancy
could be largely explained by differences in the distribution of
time elapsed since menopause (within 10 years of menopause vs.
more), with a signiﬁcant interaction found for this factor. Overall,
the results of the present study may certainly apply to safety or
beneﬁt-risk outcomes.
Finally, the present review did not explore to which extent the
identiﬁcation of an EEG may have impacted stakeholders deci-
sions. The issue of the EEG was ﬁrst raised by prescribers and
health technology assessment (HTA) bodies, but has now reached
the awareness of regulators [64]. The European Medicines Agency
and European HTAs now offer parallel scientiﬁc advice to man-
ufactures, where HTA needs for real-world data are being voiced
early in development [65]. It would be interesting to investigate
whether, and to which extent, regulatory decisions have been
made in light of the issue of the EEG, that is, using real-life
evidence. This is the objective and scope of another GetReal
study in which we systematically reviewed phase 3 preauthori-
zation trials that used more “pragmatic” designs (Karcher et al,
2015, submitted manuscript, unpublished data).Conclusions
Identifying and targeting the contextual factors that have a
meaningful impact on effect estimates for medications is a key
priority for RCT design permitting better estimates of the effec-
tiveness of drugs in addition to their efﬁcacy. Within the GetRealConsortium [7], several studies are under way to identify the drivers
of effectiveness in different therapeutic areas (schizophrenia,
Hodgkin’s lymphoma, diabetes, etc.). We hope that this review will
help future research build on the identiﬁed paradigms.
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